Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial

BACKGROUND: Type 2 diabetes mellitus (T2DM) is characterized by systemic metabolic abnormalities and the development of micro- and macrovascular complications, resulting in a shortened life expectancy. A recent cardiovascular (CV) safety trial, the EMPA-REG OUTCOME trial, showed that empagliflozin,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Atsushi, Shimabukuro, Michio, Okada, Yosuke, Taguchi, Isao, Yamaoka-Tojo, Minako, Tomiyama, Hirofumi, Teragawa, Hiroki, Sugiyama, Seigo, Yoshida, Hisako, Sato, Yasunori, Kawaguchi, Atsushi, Ikehara, Yumi, Machii, Noritaka, Maruhashi, Tatsuya, Shima, Kosuke R., Takamura, Toshinari, Matsuzawa, Yasushi, Kimura, Kazuo, Sakuma, Masashi, Oyama, Jun-ichi, Inoue, Teruo, Higashi, Yukihito, Ueda, Shinichiro, Node, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389095/
https://www.ncbi.nlm.nih.gov/pubmed/28403850
http://dx.doi.org/10.1186/s12933-017-0532-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5389095/
https://www.ncbi.nlm.nih.gov/pubmed/28403850
http://dx.doi.org/10.1186/s12933-017-0532-8

Ejemplares similares